BTK and mantle cell lymphoma: Carl H. June reported co-treatment with the Bruton tyrosine kinase (BTK) inhibitor ibrutinib along with anti-CD19 CAR T cells improves responses against mantle cell lymphoma and B cell chronic lymphocytic leukemia.